Target assessment for antiparasitic drug discovery

    Research output: Contribution to journalReview article

    99 Citations (Scopus)

    Abstract

    Drug discovery is a high-risk, expensive and lengthy process taking at least 12 years and costing upwards of US$500 million per drug to reach the clinic. For neglected diseases, the drug discovery process is driven by medical need and guided by pre-defined target product profiles. Assessment and prioritisation of the most promising targets for entry into screening programmes is crucial for maximising the chances of success. Here, we describe criteria used in our drug discovery unit for target assessment and introduce the 'traffic-light' system as a prioritisation and management tool. We hope this brief review will stimulate basic scientists to acquire additional information necessary for drug discovery.

    Original languageEnglish
    Pages (from-to)589-595
    Number of pages7
    JournalTrends in Parasitology
    Volume23
    Issue number12
    DOIs
    Publication statusPublished - Dec 2007

    Keywords

    • TRYPANOSOMA-BRUCEI
    • PLASMODIUM-FALCIPARUM
    • DIHYDROFOLATE-REDUCTASE
    • NEGLECTED DISEASES
    • TROPICAL DISEASES
    • GENE REPLACEMENT
    • RESISTANCE
    • MALARIA
    • DRUGGABILITY
    • LEISHMANIA

    Cite this

    @article{f98062d4d5654fb491b2220f811acc68,
    title = "Target assessment for antiparasitic drug discovery",
    abstract = "Drug discovery is a high-risk, expensive and lengthy process taking at least 12 years and costing upwards of US$500 million per drug to reach the clinic. For neglected diseases, the drug discovery process is driven by medical need and guided by pre-defined target product profiles. Assessment and prioritisation of the most promising targets for entry into screening programmes is crucial for maximising the chances of success. Here, we describe criteria used in our drug discovery unit for target assessment and introduce the 'traffic-light' system as a prioritisation and management tool. We hope this brief review will stimulate basic scientists to acquire additional information necessary for drug discovery.",
    keywords = "TRYPANOSOMA-BRUCEI, PLASMODIUM-FALCIPARUM, DIHYDROFOLATE-REDUCTASE, NEGLECTED DISEASES, TROPICAL DISEASES, GENE REPLACEMENT, RESISTANCE, MALARIA, DRUGGABILITY, LEISHMANIA",
    author = "Frearson, {Julie A.} and Wyatt, {Paul G.} and Gilbert, {Ian H.} and Fairlamb, {Alan H.}",
    year = "2007",
    month = "12",
    doi = "10.1016/j.pt.2007.08.019",
    language = "English",
    volume = "23",
    pages = "589--595",
    journal = "Trends in Parasitology",
    issn = "1471-4922",
    publisher = "Elsevier",
    number = "12",

    }

    Target assessment for antiparasitic drug discovery. / Frearson, Julie A.; Wyatt, Paul G.; Gilbert, Ian H.; Fairlamb, Alan H.

    In: Trends in Parasitology, Vol. 23, No. 12, 12.2007, p. 589-595.

    Research output: Contribution to journalReview article

    TY - JOUR

    T1 - Target assessment for antiparasitic drug discovery

    AU - Frearson, Julie A.

    AU - Wyatt, Paul G.

    AU - Gilbert, Ian H.

    AU - Fairlamb, Alan H.

    PY - 2007/12

    Y1 - 2007/12

    N2 - Drug discovery is a high-risk, expensive and lengthy process taking at least 12 years and costing upwards of US$500 million per drug to reach the clinic. For neglected diseases, the drug discovery process is driven by medical need and guided by pre-defined target product profiles. Assessment and prioritisation of the most promising targets for entry into screening programmes is crucial for maximising the chances of success. Here, we describe criteria used in our drug discovery unit for target assessment and introduce the 'traffic-light' system as a prioritisation and management tool. We hope this brief review will stimulate basic scientists to acquire additional information necessary for drug discovery.

    AB - Drug discovery is a high-risk, expensive and lengthy process taking at least 12 years and costing upwards of US$500 million per drug to reach the clinic. For neglected diseases, the drug discovery process is driven by medical need and guided by pre-defined target product profiles. Assessment and prioritisation of the most promising targets for entry into screening programmes is crucial for maximising the chances of success. Here, we describe criteria used in our drug discovery unit for target assessment and introduce the 'traffic-light' system as a prioritisation and management tool. We hope this brief review will stimulate basic scientists to acquire additional information necessary for drug discovery.

    KW - TRYPANOSOMA-BRUCEI

    KW - PLASMODIUM-FALCIPARUM

    KW - DIHYDROFOLATE-REDUCTASE

    KW - NEGLECTED DISEASES

    KW - TROPICAL DISEASES

    KW - GENE REPLACEMENT

    KW - RESISTANCE

    KW - MALARIA

    KW - DRUGGABILITY

    KW - LEISHMANIA

    U2 - 10.1016/j.pt.2007.08.019

    DO - 10.1016/j.pt.2007.08.019

    M3 - Review article

    VL - 23

    SP - 589

    EP - 595

    JO - Trends in Parasitology

    JF - Trends in Parasitology

    SN - 1471-4922

    IS - 12

    ER -